A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Public ClinicalTrials.gov record NCT05556343. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)
Study identification
- NCT ID
- NCT05556343
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- MYK-224 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2023
- Primary completion
- Aug 18, 2024
- Completion
- Feb 26, 2025
- Last update posted
- Jun 1, 2026
2023 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0026 | La Jolla | California | 92037 | — |
| Local Institution - 0014 | Los Angeles | California | 90048 | — |
| Local Institution - 0016 | San Francisco | California | 94158-2156 | — |
| Local Institution - 0001 | Kansas City | Kansas | 66103-2937 | — |
| Local Institution - 0032 | New York | New York | 10032-3802 | — |
| Local Institution - 0013 | Durham | North Carolina | 27710 | — |
| Local Institution - 0031 | Cincinnati | Ohio | 45267 | — |
| Local Institution - 0015 | Cleveland | Ohio | 44195-0001 | — |
| Local Institution - 0024 | Portland | Oregon | 97239-3011 | — |
| Local Institution - 0021 | Nashville | Tennessee | 37205-2202 | — |
| Local Institution - 0025 | San Antonio | Texas | 78229-3900 | — |
| Local Institution - 0006 | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05556343, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05556343 live on ClinicalTrials.gov.